Published on in Vol 11, No 5 (2022): May
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/34711, first published
.
Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
Journals
- Carolina H, Gilmar G, Casimiro C, Gustavo V. Biweekly vs Triweekly low dose intravenous ketamine acute series for severe major depression: A case report. Journal of Affective Disorders Reports 2023;14:100620 View
- Gutierrez G, Vazquez G, Ravindran N, Lam R, Giacobbe P, Ganapathy K, Kowara A, Do A, Baskaran A, Nestor S, Swainson J. Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee. Therapeutic Advances in Drug Safety 2025;16 View
- Elmaadawi A, Naha I, Prabhudesai S, Eltohamy M. Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression. Psychiatry Research 2025;354:116821 View